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ABSTRACT
Objectives: Cervical cancer is the fourth most common type of cancer among women worldwide and one of the most 
common malignancies diagnosed in gravidas. Therefore, routine antenatal Pap smear is such an important examination. 
The aim of the study was to assess the prevalence of Pap smear performance during prenatal care and to determine pos-
sible factors affecting it.
Material and methods: A self-composed questionnaire was distributed among 638 women managed in a tertiary obstetric 
referral center. 33 questions regarded cervical cancer prevention and risk factors. 
Results: 96.9% of respondents had undergone Pap smear and 80.6% had it performed during pregnancy. For 11.5% women 
Pap smear in pregnancy was the first one in their life. The most common reasons for lack of Pap smear performance were: 
no subjective need to perform it (40.9%), no doctor’s recommendation (28.6%) and lack of gynecological care (16.3%). 
Among professionally active women the percentage of those who had not undergone Pap smear during pregnancy was 
statistically higher (28.5%) than among those who were on sick leave (13.5%) (p = 0.0003). Also, younger women were at 
risk of less frequent participation in cervical cancer screening
Conclusions: Although performance of Pap smear among surveyed patients was relatively high, there was a significant 
group of women who had undergone their first test during pregnancy, which makes secondary cervical cancer prevention in 
prenatal care a useful prophylactic strategy. Special attention should be given to younger and professionally active women. 
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INTRODUCTION
According to GLOBOCAN cervical cancer is the fourth 
most common type of cancer among women worldwide, 
with the incidence of 569,847 cases and the cause of 
311,365 deaths a year [1]. In Poland, in 2018 the number 
of new cases was 3,220 with an incidence age- standard-
ized rate of 9.4 per 100,000 and the number of deaths was 
1,947 with a mortality age-standardized rate of 4.9 per 
100,000 [1]. Nevertheless, according to GLOBOCAN, the 
age-adjusted cervical cancer incidence in 2018 was lower 
in Poland than in Europe as a whole (9.4 vs 11.2) and the 
number of new cases decreased by almost 2.3 times during 
the end of the first decade of the 21st century, which was 
possibly due to the introduction of a population based 
cervical cancer screening program initiated in 2006 by the 
Polish National Health Fund [1, 2]. The program is dedicated 
to women covered by health insurance between 25 and 
59 years of age and offers performance of Pap smear once 
in three years — in case of negative results. Whereas patients 
classified as high-risk groups — HIV or HPV positive or on 
immunosuppressive therapy - can participate in examina-
tions every 12 months [2]. Over the years participation in 
the cytology screening program in Poland increased from 
12.7% in 2006 to 42.11% in 2015 [3]. This suggests that the 
universal, free access to cytology examinations may result 
in increased population coverage.
Another factor, which contributes to incidence reduc-
tion, is the vaccination against human papillomavirus (HPV) 
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which is recommended in Poland, but is not among the pub-
licly funded healthcare benefits [4]. Only two EU member 
states, including Poland, are not financing HPV vaccinations 
in selected age groups (10–15) [5]. However, various local 
governments and autonomies as well as charity organiza-
tions and schools conduct free, preventive HPV vaccination 
actions. The Polish National Vaccination Program recom-
mends HPV vaccination prior to sexual initiation, however 
it does not indicate the specific age when such vaccination 
should be performed [4]. 
Additionally, in order to improve cervical cancer screen-
ing effectiveness, according to the Ordinance of the Polish 
Minister of Health, Pap smear should be performed in every 
pregnant woman till the end of the 10th gestational week 
as a part of standard prenatal care, unless she had under-
gone it within the last six months [6]. For most women, 
pregnancy is a period of increased medical supervision, 
which makes it a good opportunity for secondary cervical 
cancer prevention. 
Objectives
The aim of the study was to assess the performance of 
Pap smear in pregnant women and to determine possible 
factors affecting it. 
MATERIAL AND METHODS
A cross-sectional study was performed by means of 
a self-composed questionnaire (see Annex no. 1) distributed 
among 638 patients from different regions of Poland who 
were managed in the 3rd trimester or within the first month af-
ter birth in a tertiary referral obstetric center. The entire group 
of patients who agreed to take part in the study was surveyed 
between December 2017 and February 2018. The survey was 
composed of 33 questions regarding obstetric history, per-
formance, frequency and results of Pap smear examinations, 
reasons for not performing it (if applicable), gynecological 
care, vaccination against HPV, use of hormonal contracep-
tion, family history of cervical cancer, and performance of 
further diagnostic procedures: colposcopy or histopatho-
logical examination. Informed consent was obtained from 
all individual participants included in the study. Statistical 
analysis was performed with the use of Statistica 13.3. Since 
the differences between groups were based on the categori-
cal variables, they were tested with the use of chi-squared 
test. P-values < 0.05 were considered statistically significant.
RESULTS
The average age of surveyed women was 25.8 ± 4.89 years 
(17–45 years). The study group was diverse in terms of place 
of residence, level of education, professional activity and 
marital status, which is presented in Table 1. 
More than half of respondents were primigravid (54.4%; 
n = 347), 29.9% (n = 191) were in their second pregnancy 
and for 15.7% (n = 100) of women it was the third or sub-
sequent pregnancy.
All surveyed women were under gynecological super-
vision during pregnancy but as many as 10.2% (n = 65) 
of them had never visited a gynecologist before pregnancy. 
Out of those who were attending appointments regularly 
before pregnancy, 34.1% (n = 206) did it once in 6 months 
or more often, 41.9% (n = 253) once a year, 12.7% (n = 77) 
once in 2 or 3 years and 6% (n = 36) less often.
The analysis of Pap smear performance among surveyed 
women revealed that the vast majority of them (96.9%; 
n = 618) had undergone Pap smear examination, yet fewer 
(80.6%; n = 497) did it during pregnancy. This includes 
a small group of women (4.9%; n = 23) who performed 
the test as a preparation for planned pregnancy. Among 
women who underwent Pap smear during pregnancy those 
who had it in the first trimester (72.2%; n = 324) dominated, 
whereas 23.6% (n = 106) had it in the second and 4.2% 
(n = 19) in the third trimester. Among multiparas the per-
Table 1. Group characteristics: number of women (%)
Level of highest achieved education
Primary Vocational Secondary Higher
19 (3%) 36 (6%) 238 (37%) 345 (54%)
Place of residence
Village City < 10,000 inhabitants City 10,000–100,000 inhabitants City > 100,000 inhabitants
128 (20%) 55 (9%) 149 (23%) 306 (48%)
Professional activity
Unemployed Professionally active Sick leave during pregnancy Maternity leave Other
99 (16%) 137 (21%) 283 (44%) 75 (12%) 44 (7%)
Marital status
Married Unmarried
457 (72%) 181 (28%)
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centage of Pap smear performance in previous pregnancies 
was 79.9% (n = 226).
The analysis of Pap smear results performed during preg-
nancy revealed that in 67.8% (n = 328) of cases they were 
normal, in 23.6% (n = 114) the test detected inflammation 
and 2.3% (n = 11) of women had an abnormal test result such 
as: atypical squamous cells of undetermined significance 
(ASC-US), low grade squamous intraepithelial lesion (LSIL) 
or high grade squamous intraepithelial lesion (HSIL) (Fig. 1).
The analysis of questions regarding frequency of Pap 
smear performance showed that almost half of the women 
(47.4%; n = 293) performed the test regularly every year, 22.7% 
(n = 140) every 2 years, 7.8% (n = 47) every 3 years and 7.9% 
(n = 49) less often. For 11.5% (n = 71) of women Pap smear 
in pregnancy was the first in their lifetime and 1% (n = 6) 
underwent the test mainly in pregnancies. The average age 
during the first Pap smear was 20.6 ± 3.4 years (12–35 years). 
Similarly, among women who were over 25 years old 
and were qualified for the population-based cervical cancer 
screening program, almost half (48.1%; n = 232) performed 
the test once a year, 24.5% (n = 118) every 2 years, 9.3% 
(n = 45) every 3 years and 8.5% (n = 41) less often. For 7.5% 
(n = 36) of women Pap smear in pregnancy was the first in 
their lifetime.
The most common reasons for not performing Pap 
smear were: no subjective need to perform it (40.9%; n = 83), 
no doctor’s recommendation (28.6%; n = 58) and lack of 
gynecological care (16.3%; n = 33). No doctor’s recommen-
dation was reported by 26% (n = 39) women who were 
over 25 years old and were covered by a population-based 
screening program. Other listed reasons were: feeling of 
shame (5.4%; n = 11), cost of the test (3%; n = 6), fear of pain 
(2.5%; n = 5) and concern about the test result (2%; n = 4).
As for the reasons which affected the Pap smear perfor-
mance, it was observed that among professionally active 
women the percentage of those who did not perform Pap 
smear during pregnancy was statistically higher (n = 41; 
28.5%) than among those who were on sick leave (n = 37; 
13.5%) (p = 0.0003). Another statistically significant factor 
was women’s age (Tab. 2). Analysis of the following age 
groups: under 25 years (< 25), between 25 and 35 years 
(≤ 25 and < 35) and over 35 years (> 35) revealed that the 
youngest women much more often had never performed 
Pap smear (9.1% vs. 1.2% in other age groups; p = 0.0001) and 
that the test during pregnancy was more often the first one in 
their life (25.7% vs. 7.2% in other age groups; p = 0.0001). The 
most important fact is that they much more frequently did 
not perform Pap smear in their current pregnancy (27.1% vs. 
16.7% in other age groups; p = 0.02). No significant associa-
tion between place of residence, level of education or marital 
status and Pap smear performance was observed.
8.8% of women (n = 56) admitted to having a positive 
family history of cervical cancer. Yet the majority of them 
(67.9%; n = 38) did not indicate any impact of this fact on 
the frequency of Pap smear performance. 50.9% (n = 324) of 
women declared their use of hormonal contraception (HC) 
in the past, 85.4% (n = 274) of them reported no association 
between HC use and regular Pap smear control. 
The study also showed that vaccination against HPV 
was not widespread among respondents (6.1%; n = 39). Those 
who had been vaccinated were asked whether they had un-
dergone it before or after sexual initiation, but no marked 
predominance of either option was observed (38.5% vs. 
46.2%, respectively). 
A history of further diagnostic procedures due to suspi-
cion of cervical abnormalities was reported by 10.1% (n = 64) 
of surveyed women, revealing one case of LSIL and four 
cases of HSIL in histology examinations. 
DISCUSSION
Despite the development of a National Popula-
tion-Based Cervical Cancer Screening Program in 2006 by 
the Polish Ministry of Health, the National Health Fund and 
Table 2. Pap smear performance in different age groups: number of patients (%)
< 25 years
n = 150
25–34 years
n = 404
≥ 35 years
n = 70 P
Had never performed Pap smear 14 (9.1%) 4 (1.2%) 1 (1.4%) 0.0001
Pap smear in pregnancy was the first in a lifetime 39 (25.7%) 31 (7.6%) 4 (5.6%) 0.0001
Did not perform Pap smear in current pregnancy 41 (27.1%) 69 (17%) 12 (17.1%) 0.02
LSIL; 1.32%
normal but
inammation;
25.17%
HSIL; 0.44%
ASC-US; 0.66%
normal; 72.41%
Figure 1. Results of performed Pap smears in current pregnancy
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the Polish Gynecological Society, following World Health Or-
ganization and International Agency for Research on Cancer 
(WHO/IARC) guidelines, percentage of women performing 
the test was still unsatisfactorily low according to the Su-
preme Audit Office of Poland performed in the Lubelskie 
Province [7]. In order to increase cervical cancer screening 
coverage, since 2012 every pregnant woman should un-
dergo Pap smear during her initial prenatal visit as ordinated 
by the Polish Ministry of Health [8]. However, it is stated 
that cervical samples collected during pregnancy are more 
difficult to interpret because of hormonal changes in the 
epithelial cells [9]. Similarly, WHO provides the information 
that cervical specimens taken during pregnancy can give 
misleading results [10]. Nevertheless, results of Pap smear 
performed in pregnant women are not less accurate than in 
non-pregnant patients and it is recommended to perform 
the test if the woman is likely to give up gynecological 
care after delivery and when she is in the target age group 
[11, 12]. This includes women over 20 years old or sexually 
active for more than 3 years [13]. On the contrary, several 
publications reported that pregnancy did not modify or 
affect HPV infection, nor cervical cytomorphology [14, 15]. 
It is also proved that the intraepithelial lesions in gravidas are 
cytometrically identical to those in nonpregnat women [13]. 
Therefore, a specimen collected during pregnancy is ad-
equate for evaluation but only if the pathologist is notified 
of patient’s pregnancy status [9, 16]. It may be even more dif-
ficult to interpret the colposcopic appearance of the cervix, 
even in the first trimester. Nevertheless, it should be always 
performed in women with an abnormal Pap test result [13].
Cervical cancer is one of the most common malignancies 
diagnosed in gravidas, complicating 1 in 2200 pregnan-
cies [13, 17]. Therefore, routine antenatal Pap smear is such 
an important examination. Abnormal cervical cytology is 
observed in about 5% of gravidas [17–19]. In our study the 
percentage was slightly lower than the average — 2.3%. 
Pregnancy is a special period and sometimes the only one 
when women pay more attention to their health condition 
so especially during this time physicians should motivate 
their patients to conduct screening examinations. In the 
Norwegian study Nygård et al. [20] indicated that screening 
during pregnancy increases the coverage of the cervical can-
cer prevention program. They reported that 69% of pregnant 
women had the Pap smear performed during one year of 
follow-up since the beginning of pregnancy and that the 
majority of tests were performed before the delivery [21]. 
Our study showed that the percentage of Pap smear perfor-
mance during pregnancy in Poland was even higher (80.6%). 
However, more important is the fact that for 11.5% of wom-
en cervical cytology performed during pregnancy was the 
first in their life and it does not apply only to women who 
were under the age of 25, not routinely covered by screen-
ing. As many as 16.7% of women over 25 years of age had 
never had the test performed before pregnancy, while ac-
cording to the screening guidelines — should have had [22]. 
Similarly, a French study conducted by Brun-Micaleff et al. 
suggested that Pap smear combined with HPV infection test-
ing may be an effective method of covering young women 
with poor adherence to cervical cancer screening. It is esti-
mated that in France 40% of women do not perform regular 
cytology examinations. By enrolling in the study women 
with poor adherence the researchers detected high risk 
HPV-infections in 20.2% gravidas and cervical intraepithelial 
neoplasia grade 1 or 2 in 2% of the tested population [23].
It may be the subject of controversy whether it is wrong 
that women under the age of 25 much more often do not 
perform Pap tests. It is believed that the majority of dysplas-
tic cervical lesions, which are common in this age group have 
a tendency to regress spontaneously [21]. Therefore, covering 
this age group with screening may lead to overdiagnosis and 
subsequently — overtreatment of precancerous lesions [24]. 
However, Nygård et al. [20] showed that women who per-
form Pap smear frequently have a tendency to follow this 
pattern, whereas those who do it seldomly or never, have 
no tendency to participate in screening in the near future. 
This is why teaching young women a regular Pap smear 
scheme may lead to increased screening coverage when 
they are older. This approach is also in line with the study 
conducted by Brun-Micaleff et al. Although they detected 
that 20% of the young pregnant women were positive for 
HPV infection, they were aware that most of them developed 
transient infections. Nevertheless, they stated that a posi-
tive result may prompt women to repeat Pap smears in the 
following years at regular intervals [23]. 
In a Polish study regarding awareness of cervical cancer 
prevention performed by Ulman-Włodarz et al. [25] the most 
common reasons for avoiding Pap smear performance were: 
fear of pain (40.9%), no symptoms of the disease (18%) and 
carelessness (15%). These causes are quite different in our 
results, where no subjective need to perform the test was 
the most frequently reported reason (40.9%) and fear of pain 
was quoted only by 2.5% of respondents. Nevertheless, the 
alarming fact is that in both studies a significant number of 
patients — 28.6% in our study and 11.0% in Ulman-Włodarz 
et al. [25] study — reported no doctor’s recommendation 
to perform the test. Monteiro et al. [26] showed that the 
problem does not only concern the Polish society. In their 
study from Brazil the majority of gravidas who did not un-
dergo cytological examination did not receive an offer from 
healthcare professional to do so. They emphasized that 
it was crucial to perform the Pap smear during antenatal 
consultations as women less frequently schedule an ap-
pointment exclusively in order to undergo Pap smear but 
they usually participate in prenatal consultations, which 
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makes pregnancy a good opportunity for screening. Simi-
lar recommendations are given by the authors of the Thai 
research [18]. In their study 31% of gravidas had no previ-
ous Pap smear screening. Therefore, the proposition of the 
examination is clinically relevant because these women may 
not attend regular gynecological appointments in future. 
In addition, in a Swedish study by Eaker et al. [27] respond-
ents stated that receiving an invitation or offer from a gy-
necologist motivated them to perform the test. Thus, it is 
crucial to put emphasis on the greater frequency of these 
proposals. In addition, the most commonly reported reason 
for avoiding Pap smear performance, which was ‘no sub-
jective need to perform the test’, can be interpreted as no 
disease symptoms. This misunderstanding that Pap smear 
should be performed only in the presence of gynecological 
symptoms is quite common among patients all over the 
world. Augusto et al. [28] in their Brazilian study proved that 
the absence of symptomatic episodes of sexually transmit-
ted disease was one of the most common reasons for no 
participation in the screening program. Also, research by 
Khaengkhor et al. [18] revealed that for 53% of women 
Pap smear performance seemed necessary only in case of 
symptoms, such as vaginal bleeding or leucorrhea. 
Authors of different studies tried to identify factors af-
fecting the Pap smear performance in order to define un-
der-screened groups requiring special attention. Spaczyński 
et al. [29] reported that the place of residence and level of 
education have an impact on cervical cancer screening. 
According to their study, living in the village and low level 
of education contribute to less frequent secondary preven-
tion. On the contrary, our study did not show any influence 
of the place of residence, level of education or marital status 
on cervical cancer screening — both during pregnancy and 
in general. The only association we observed was the fact 
that women who were professionally active during preg-
nancy less often underwent Pap smear in comparison to 
women who were on sick leave (28.5% vs. 13.5%; p = 0.0003). 
This problem does not only affect our population — in the 
Brazilian study Augusto et al. [28] revealed that for 30.4% 
of women no participation in the screening program was 
caused by time-consuming job responsibilities and childcare. 
It may indicate that numerous duties affect prenatal testing 
and that this group of women requires more attention.
Ulman-Włodarz et al. [25] mentioned that almost 31% 
of patients who had an incidence of cervical cancer in their 
family were more motivated to perform Pap smear. It is 
consistent with the results obtained in our study (32.1%). 
Other forms of cervical cancer prophylaxis such as vaccina-
tion against HPV for primary prevention is not widespread 
in Poland — Ulman-Włodarz et al. [25] reported that only 
4% of respondents were vaccinated, whereas in our study 
it was declared by 6.1% of surveyed women.
CONCLUSIONS
In conclusion, although the prevalence of Pap smear 
performance in analyzed population was relatively high, 
there was a substantial group of women who performed 
their first Pap smear as a part of prenatal care. Therefore, 
secondary cervical cancer prevention should remain an im-
portant element of prenatal consultations, combined with 
educating women about the necessity of regular control in 
future and more frequent doctors’ proposals to perform it. 
Special attention should be given to younger and profes-
sionally active women as they are at risk of less frequent 
participation in cervical cancer screening in comparison 
to older women and those who resign from work during 
pregnancy. 
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Annex 1. PAP SMEAR IN PREGNANCY — QUESTIONNAIRE
1. How old are you? ....................
2. Place of residence:
Countryside
City < 10,000 inhabitants
City of 10,000–100,000 inhabitants
City > 100,000 inhabitants
3. Education:
Basic
Professional
Medium
Higher incomplete
Higher
4. Professional activity:
Professionally active
Sick leave during pregnancy
Social benefits
Unemployed
Maternity leave
5. Marital status:
Single
Married
Separated
After divorce
Widow
6. How many times have you been pregnant (including your current pregnancy)?
0 1 2 3 4 5 6 7 8 9+
7. How many times have you given birth?
0 1 2 3 4 5 6 7 8 9+
Pap smear is a screening test that gives an opportunity to diagnose 
and monitor cervical cancer. It relates to the diagnosis of cancer, 
based on microscopic evaluation of cells taken from the cervical 
smear. Thanks to cytology, most abnormalities can be detected  
at an early stage.
8. Have you ever had undergone Pap smear examination?
Yes
No
9.
If you answered “Yes” to question number 8: How many times 
have you had undergone Pap smear examination? 
......................................................................
10. If you answered “Yes” to question number 8: How often do you undergo Pap smear?
Every 1 year
Every 2 years
Every 3 years
Less often
Other: ...........................................
11. If you answered “Yes” to question number 8: How old were you at the time of your first cytology? ...........................................
12. If you answered “Yes” to question number 8: Did you perform cytology during your current pregnancy?
Yes
No
I performed it before pregnancy
12 a. In which week of pregnancy did you perform cytology? ...............................................................
12 b. What was the result of the examination? ........................................
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12 c. The evaluation of the last cytology was made with the use of scale:
Papanicolau Scale: result as group I, II, III, IV or V.
Bethesda scale: normal result, ASCUS, LSIL, HSIL, AGUS, 
ASC-H, cancer cells
I do not know
13.
If you answered “Yes” to question number 8 and were 
pregnant before: Did you perform cytology during your 
previous pregnancy(ies)?
Yes
No
14.
If you answered “Yes” to question number 8: When was 
the last time you have had undergone Pap smear (before 
pregnancy)?
< 1 year
1–2 years ago
2–3 years ago
3 years
I do not remember
Never
15. If you answered “Yes” to question number 8: What were the results of these cytology examinations?
Always correct
Mostly correct
Usually incorrect — exactly how? ......................................................
Always incorrect — exactly how? .......................................................
I do not remember
16.
If you answered “Yes” to question number 8: Did the 
abnormal cytology result affected the frequency of your Pap 
smear performance?
Yes
No
17. If you have not undergone Pap smear before, why was that?
No subjective need to perform it
Concern about the test result
No doctor’s recommendation
Lack of gynecological care
Fear of pain
Feeling of shame
Cost of the test
Other — what? ..........................................................................................
18. Have you ever been to a gynecologist before your pregnancy?
Yes
No
19. If you answered “Yes” to question number 18: How often did you go to the gynecologist for a check-up before pregnancy?
Once every 6 months or more often
Once a year
Once every 2–3 years
Less often than every three years
Never
20. Have you been vaccinated against HPV (human papilloma virus causing cervical cancer)?
Yes
No
20 a. If you answered “Yes” to question number 20, has it been before your sexual initiation?
Yes
No.
21. Has anyone in your family had cervical cancer?
Yes — who? ...........................................................................
No
I do not know
21 a. If you answered “Yes” to question number 21, has it affected the frequency of your Pap smear performance?
Yes
No
22. Did you use hormonal contraception before getting pregnant?
Yes
No
22 a. If you answered “Yes” to question number 22, what kind of contraception did you use?
Oral contraception
Intrauterine device
Vaginal ring
Subcutaneous implant
Injections
Contraceptive patch
Other - what? .................................................................................
22 b. Have you performed Pap smear more often while using hormonal contraception?
Yes
No
23.
Have you ever had a colposcopy (endoscopic examination of 
the cervix, assessing the cervix by a doctor using an optical 
device - colposcope)?
Yes
No
I do not know
23 a. If you answered “Yes” to question number 23, do you remember the result of the colposcopy?
Correct result
Incorrect result: .......................................
24. Have you had a histopathological examination of the cervical tissue?
Yes
No
I do not know
24 a. If you answered “Yes” to question number 23, do you remember the result of the histopathological examination?
Correct result
Incorrect result: .......................................
